Equities analysts forecast that Sangamo Therapeutics, Inc. (NASDAQ:SGMO) will announce earnings of ($0.18) per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Sangamo Therapeutics’ earnings. The lowest EPS estimate is ($0.22) and the highest is ($0.11). Sangamo Therapeutics reported earnings of ($0.14) per share in the same quarter last year, which indicates a negative year over year growth rate of 28.6%. The company is scheduled to report its next quarterly earnings report on Tuesday, February 27th.

According to Zacks, analysts expect that Sangamo Therapeutics will report full-year earnings of ($0.73) per share for the current fiscal year, with EPS estimates ranging from ($0.81) to ($0.65). For the next year, analysts anticipate that the company will post earnings of ($0.73) per share, with EPS estimates ranging from ($1.07) to ($0.01). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Sangamo Therapeutics.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.04. The firm had revenue of $11.81 million for the quarter, compared to analyst estimates of $10.37 million. Sangamo Therapeutics had a negative return on equity of 31.81% and a negative net margin of 157.66%. The company’s revenue for the quarter was up 333.0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.27) earnings per share.

Several research analysts have weighed in on SGMO shares. Wedbush reiterated a “hold” rating and set a $6.00 target price on shares of Sangamo Therapeutics in a report on Wednesday, November 15th. Zacks Investment Research upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a report on Friday, August 18th. Jefferies Group reiterated a “buy” rating and set a $18.00 target price on shares of Sangamo Therapeutics in a report on Thursday, September 14th. Barclays started coverage on Sangamo Therapeutics in a report on Wednesday, November 22nd. They set an “overweight” rating and a $20.00 target price on the stock. Finally, Piper Jaffray Companies set a $8.00 target price on Sangamo Therapeutics and gave the stock a “hold” rating in a report on Thursday, August 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $17.83.

Sangamo Therapeutics (SGMO) opened at $17.20 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.64 and a quick ratio of 5.64. Sangamo Therapeutics has a twelve month low of $2.65 and a twelve month high of $18.40.

In other Sangamo Therapeutics news, Director William R. Ringo sold 31,000 shares of Sangamo Therapeutics stock in a transaction dated Wednesday, September 20th. The stock was sold at an average price of $14.37, for a total value of $445,470.00. Following the sale, the director now owns 31,800 shares of the company’s stock, valued at approximately $456,966. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Curt A. Herberts III sold 15,000 shares of Sangamo Therapeutics stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $15.25, for a total value of $228,750.00. The disclosure for this sale can be found here. Insiders sold a total of 79,433 shares of company stock worth $1,228,266 in the last three months. Company insiders own 5.50% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in shares of Sangamo Therapeutics by 12.4% in the second quarter. Vanguard Group Inc. now owns 3,471,681 shares of the biopharmaceutical company’s stock valued at $30,551,000 after acquiring an additional 384,031 shares during the last quarter. State Street Corp increased its position in shares of Sangamo Therapeutics by 51.6% in the second quarter. State Street Corp now owns 1,868,285 shares of the biopharmaceutical company’s stock valued at $16,441,000 after acquiring an additional 636,296 shares during the last quarter. RA Capital Management LLC acquired a new stake in shares of Sangamo Therapeutics in the second quarter valued at about $11,000,000. Northern Trust Corp increased its position in shares of Sangamo Therapeutics by 4.9% in the second quarter. Northern Trust Corp now owns 947,832 shares of the biopharmaceutical company’s stock valued at $8,341,000 after acquiring an additional 44,656 shares during the last quarter. Finally, Point72 Asset Management L.P. increased its position in shares of Sangamo Therapeutics by 93.8% in the third quarter. Point72 Asset Management L.P. now owns 693,300 shares of the biopharmaceutical company’s stock valued at $10,400,000 after acquiring an additional 335,595 shares during the last quarter. 64.35% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “-$0.18 EPS Expected for Sangamo Therapeutics, Inc. (SGMO) This Quarter” was first published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US & international copyright law. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/08/0-18-eps-expected-for-sangamo-therapeutics-inc-sgmo-this-quarter.html.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Get a free copy of the Zacks research report on Sangamo Therapeutics (SGMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.